Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone

Toxicology Letters

Volumn 201, Issue 2, 2011, Pages 110-115

  Mikaelian, I ^a   Buness, A ^b   Hirkaler, G ^a   Fernandes, R ^a   Coluccio, D ^a   Geng, W ^a   Visalli, T ^a   Bachynsky, M O ^a   Berkofsky Fessler, W ^a   Kanwal, C ^a   Hilton, H ^a   Nicklaus, R ^a   Hoflack, J C ^b   Dunn, M ^a   Sanders, M ^a   Giron, M ^a   Boyle, B W ^a   Singer, T ^b   Dick, L Suter ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cardiac; Cardiotoxicity; Heart; Hypertrophy; Troponins

Indexed keywords

ROSIGLITAZONE; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART; HEART MUSCLE INJURY; HEART WEIGHT; HEMATOLOGY; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; GENE EXPRESSION PROFILING; HEART; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIUM; ORGAN SIZE; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; TROPONIN I;

RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 79651469653     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.12.012     Document Type: Article

References (30)

1. Adamcova M., Sterba M., Simunek T., Potacova A., Popelova O., Mazurova Y., Gersl V. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin. Drug Saf. 2005, 4:457-472.
2. Afsar B., Elsurer R., Akgul A., Sezer S., Ozdemir F.N. Factors related to silent myocardial damage in hemodialysis patients. Renal Failure 2009, 31:933-941.
3. Ajjan R.A., Grant P.J. The cardiovascular safety of rosiglitazone. Expert Opin. Drug Saf. 2008, 7:367-376.
4. Arakawa K., Ishihara T., Aoto M., Inamasu M., Kitamura K., Saito A. An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin. Exp. Pharmacol. Physiol. 2004, 31:8-13.
5. Bates K.J., Hall E.M., Fahie-Wilson M.N., Kindler H., Bailey C., Lythall D., Lamb E.J. Circulating immunoreactive cardiac troponin forms determined by gel filtration chromatography after acute myocardial infarction. Clin. Chem. 2010, 56:952-958.
6. Breider M.A., Gough A.W., Haskins J.R., Sobocinski G., de la Iglesia F.A. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol. Pathol. 1999, 27:545-552.
7. Coluccio, D., Nicklaus, R., Hirkaler, G., Geng, W., Dunn, M., Todd, J., Estis, J., Lu, Q. A., Singer, T., Mikaelian, I., Comparison of the Singulex Erenna™ and Beckman Coulter Access® 2 Immunoassays for the Quantification of Cardiac Troponin I in Rats. in preparation.
8. Duan S.Z., Ivashchenko C.Y., Russell M.W., Milstone D.S., Mortensen R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ. Res. 2005, 97:372-379.
9. Edgley A.J., Thalen P.G., Dahllof B., Lanne B., Ljung B., Oakes N.D. PPARgamma agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats. Eur. J. Pharmacol. 2006, 538:195-206.
10. El-Hage G. Muraglitazar 2005, FDA, Washington, DC.
11. Festuccia W.T., Laplante M., Brule S., Houde V.P., Achouba A., Lachance D., Pedrosa M.L., Silva M.E., Guerra-Sa R., Couet J., Arsenault M., Marette A., Deshaies Y. Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. J. Mol. Cell. Cardiol. 2009, 47:85-95.
12. Gilde A.J., van der Lee K.A., Willemsen P.H., Chinetti G., van der Leij F.R., van der Vusse G.J., Staels B., van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 2003, 92:518-524.
13. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., Magnuson M.A., Redha R., Zhang Y., Breyer M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 2005, 11:861-866.
14. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31:e15.
15. Karalliedde J., Buckingham R., Starkie M., Lorand D., Stewart M., Viberti G. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J. Am. Soc. Nephrol. 2006, 17:3482-3490.
16. Katus H.A., Remppis A., Scheffold T., Diederich K.W., Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am. J. Cardiol. 1991, 67:1360-1367.
17. Kelley W.E., Januzzi J.L., Christenson R.H. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin. Chem. 2009, 55:2098-2112.
18. Krishnan J., Suter M., Windak R., Krebs T., Felley A., Montessuit C., Tokarska-Schlattner M., Aasum E., Bogdanova A., Perriard E., Perriard J.C., Larsen T., Pedrazzini T., Krek W. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 2009, 9:512-524.
19. Lygate C.A., Hulbert K., Monfared M., Cole M.A., Clarke K., Neubauer S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc. Res. 2003, 58:632-637.
20. Mikaelian I., Coluccio D., Hirkaler G.M., Downing J.C., Rasmussen E., Todd J., Estis J., Lu Q.A., Nicklaus R. Assessment of the toxicity of hydralazine in the rat using an ultrasensitive flow-based cardiac troponin I immunoassay. Toxicol. Pathol. 2009, 37:878-881.
21. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941-2948.
22. Regwan S., Hulten E.A., Martinho S., Slim J., Villines T.C., Mitchell J., Slim A.M. Marathon running as a cause of troponin elevation: a systematic review and meta-analysis. J. Intervention. Cardiol. 2010, 23:443-450.
23. Sabatine M.S., Morrow D.A., de Lemos J.A., Jarolim P., Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur. Heart J. 2009, 30:162-169.
24. Schultze A.E., Carpenter K.H., Wians F.H., Agee S.J., Minyard J., Lu Q.A., Todd J., Konrad R.J. Longitudinal studies of cardiac troponin-I concentrations in serum from male Sprague Dawley rats: baseline reference ranges and effects of handling and placebo dosing on biological variability. Toxicol. Pathol. 2009, 37:754-760.
25. Schultze A.E., Konrad R.J., Credille K.M., Lu Q.A., Todd J. Ultrasensitive cross-species measurement of cardiac troponin-I using the Erenna immunoassay system. Toxicol. Pathol. 2008, 36:777-782.
26. Sena S., Rasmussen I.R., Wende A.R., McQueen A.P., Theobald H.A., Wilde N., Pereira R.O., Litwin S.E., Berger J.P., Abel E.D. Cardiac hypertrophy caused by peroxisome proliferator-activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling. Endocrinology 2007, 148:6047-6053.
27. Shah P., Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin. Drug Saf. 2010, 9:347-354.
28. Shimoyama M., Ogino K., Tanaka Y., Ikeda T., Hisatome I. Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999, 48:609-615.
29. Strøm C.C., Aplin M., Ploug T., Christoffersen T.E., Langfort J., Viese M., Galbo H., Haunso S., Sheikh S.P. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J. 2005, 272:2684-2695.
30. Watkins S.M., Reifsnyder P.R., Pan H.J., German J.B., Leiter E.H. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J. Lipid Res. 2002, 43:1809-1817.